There are currently 89 clinical trials in Riverside, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Kaiser Permanente-Riverside, GSK Investigational Site, Artemis Institute for Clinical Research and CITrials. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Kaiser Permanente Riverside Medical Center, 10800 Magnolia Ave, Riverside, California
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Compassionate Cancer Care, Riverside, California
Conditions: Warm Autoimmune Hemolytic Anemia
Register for Updates
Vamikibart in Participants With Uveitic Macular Edema
NCT05642325
Recruiting
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Kaiser Permanente Riverside Medical Center, Riverside, California
Conditions: Uveitic Macular Edema
Register for Updates
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Practice Wang, Riverside, California
Conditions: Moderate Plaque Psoriasis
Register for Updates
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
NCT06229145
Recruiting
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Medvin Clinical Research - Cactus Avenue, Riverside, California
Conditions: Gout
Register for Updates
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413
Recruiting
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positiv... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
03/20/2024
Locations: Clinical Trial Site, Riverside, California
Conditions: Schizophrenia
Register for Updates
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
NCT03373045
Recruiting
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based survey... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Riverside, California
Conditions: Asthma
Register for Updates
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227690
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: Riverside, California, Riverside, California
Conditions: Schizophrenia
Register for Updates
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
Recruiting
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: Riverside, California, Riverside, California
Conditions: Schizophrenia
Register for Updates
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
03/11/2024
Locations: Kaiser Permanente, Riverside, California
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/11/2024
Locations: Kaiser Permanente Riverside Medical Center, Riverside, California
Conditions: Intracerebral Hemorrhage
Register for Updates
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
NCT06176196
Recruiting
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2024
Locations: Probe Clinical Research, Riverside, California
Conditions: Painful Lumbosacral Radiculopathy
Register for Updates